Delirium in the general intensive care unit (ICU) population is common, associated with adverse outcomes and well studied. However, knowledge on delirium in the increasing number of ICU patients with malignancy is scarce. The aim was to assess the frequency of delirium and its impact on resource utilizations and outcomes in ICU patients with malignancy. This retrospective, single-center longitudinal cohort study included all patients with malignancy admitted to ICUs of a University Hospital during one year. Delirium was diagnosed by an Intensive Care Delirium Screening Checklist (ICDSC) score ≥ 4. Of 488 ICU patients with malignancy, 176/488 (36%) developed delirium. Delirious patients were older (66 [55–72] vs. 61 [51–69] years, p = 0.001), had higher SAPS II (41 [27–68] vs. 24 [17–32], p < 0.001) and more frequently sepsis (26/176 [15%] vs. 6/312 [1.9%], p < 0.001) and/or shock (30/176 [6.1%] vs. 6/312 [1.9%], p < 0.001). In multivariate analysis, delirium was independently associated with lower discharge home (OR [95% CI] 0.37 [0.24–0.57], p < 0.001), longer ICU (HR [95% CI] 0.30 [0.23–0.37], p < 0.001) and hospital length of stay (HR [95% CI] 0.62 [0.50–0.77], p < 0.001), longer mechanical ventilation (HR [95% CI] 0.40 [0.28–0.57], p < 0.001), higher ICU nursing workload (B [95% CI] 1.92 [1.67–2.21], p < 0.001) and ICU (B [95% CI] 2.08 [1.81–2.38], p < 0.001) and total costs (B [95% CI] 1.44 [1.30–1.60], p < 0.001). However, delirium was not independently associated with in-hospital mortality (OR [95% CI] 2.26 [0.93–5.54], p = 0.074). In conclusion, delirium was a frequent complication in ICU patients with malignancy independently associated with high resource utilizations, however, it was not independently associated with in-hospital mortality.
Background: Whereas delirium in the general intensive care unit (ICU) population is common and well studied, knowledge on ICU delirium in patients with malignancy is scarce. The aim was to assess the frequency of delirium and its impact on resource utilizations and outcomes in ICU patients with malignancy.Methods: This retrospective, single-center longitudinal cohort study included all patients with malignancy admitted to ICUs of a University Hospital during one year. Delirium was diagnosed by an Intensive Care Delirium Screening Checklist (ICDSC) score ≥ 4. Groups were compared with Fisher’s exact and Mann-Whitney U tests. Multivariate analysis included binary logistic regression, Cox regression and multiple linear regression. Results are given as number (percentage; confidence interval (CI)) and median (interquartile range).Results: Of 488 ICU patients with malignancy, 176/488 (36%) developed delirium. Frequencies were high in patients with hepatic (13/21 [62%]; 95% CI 41-82%), lung (29/65 [45%]; 95% CI 33-56%) and colorectal malignancies (15/37 [41%]; 95% CI 24-56%). Delirious patients were older (66 [55-72] vs 61 [51-69] years, p = 0.001), had higher SAPS II (41 [27-68] vs 24 [17-32], p < 0.001) and more frequently sepsis (26/176 [15%] vs 6/312 [1.9%], p < 0.001) and / or shock (30/176 [6.1%] vs 6/312 [1.9%], p < 0.001). In multivariate analysis, delirium was independently associated with lower discharge home (OR [95% CI] 0.366 [0.236-0.567], p < 0.001), longer ICU (HR [95% CI] 0.295 [0.234-0.371], p < 0.001) and hospital length of stay (HR [95% CI] 0.619 [0.500-0.765], p < 0.001), longer mechanical ventilation (HR [95% CI] 0.401 [0.282-0.572], p < 0.001), higher ICU nursing workload (B [95% CI] 1.917 [1.665-2.206], p < 0.001) and ICU (B [95% CI] 2.077 [1.811-2.382], p < 0.001) and total costs (B [95% CI] 1.442 [1.301-1.597], p < 0.001). However, delirium was not independently associated with in-hospital mortality (OR [95% CI] 2.263 [0.925-5.537], p = 0.074).Conclusions: In ICU patients with malignancy, delirium was a frequent complication independently associated with high resource utilizations, however, it was not independently associated with in-hospital mortality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.